Topical Umbilical Cord Serum for Corneal Epithelial Defects after Diabetic Vitrectomy

• Main Authors: Siamak Moradian, Marzieh Ebrahimi, Azade Kanaani, Amir Faramarzi, Sare Safi
• Format: Article
• Language: English
• Published: Knowledge E 2020-04-01
• Series: Journal of Ophthalmic & Vision Research
• Subjects: corneal epithelial defect; diabetic vitrectomy; topical umbilical cord serum
• Online Access: https://doi.org/10.18502/jovr.v15i2.6732

Purpose: To evaluate the role of topical umbilical cord serum (TUCS) therapy in treating corneal epithelial defects (CEDs) after diabetic vitrectomy. Methods: In this double-masked, randomized clinical trial, we included 80 eyes of 80 patients who were candidates for vitrectomy due to proliferative diabetic retinopathy complications. In cases of corneal edema obscuring the fundus view during surgery, the corneal epithelium was removed using a 6-mm trephine and a blade no.15. The day after the surgery, patients were randomly divided into two groups: (1) the TUCS group that received 20% TUCS six times/day in addition to the conventional treatment of CED and (2) the control group, which was prescribed artificial tears as placebo in addition to the conventional treatment of CED. The rate of healing of CEDs was measured via two maximum linear dimensions perpendicular to each other at the start of therapy and on postoperative days 1–5, 7, and 12. Results: Of 80 eyes, 40 were assigned to each treatment group. The mean times to complete CED healing were 2.4 ± 0.7 and 3.8 ± 2.1 days in the TUCS and control groups, respectively (P < 0.001). Persistent CED occurred in two eyes in the control group but in no eyes in the TUCS group. Conclusion: TUCS therapy may be safe and effective in healing CEDs after vitrectomy in patients with diabetes.